Cosciens BiopharmaCSCIF +3.90%60 PS Ratio is 0.89 as of Jun. 27, 2026, which is 65% below its 10-year median of 2.53. GuruFocus rates CSCIF with a GF Score™ of 60/100 and a GF Value™ of $2.39 (Modestly Undervalued). The stock has 6 warning signs investors should review. Among 936 Biotechnology companies, Cosciens Biopharma ranks better than 93.38% on this metric.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Cosciens Biopharma's share price is $2.13.
Cosciens Biopharma's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 was $2.40. Hence, Cosciens Biopharma's PS Ratio for today is 0.89.
The historical rank and industry rank for Cosciens Biopharma's PS Ratio or its related term are showing as below:
CSCIF'
s PS Ratio Range Over the Past 10 Years
Min: 0.34 Med: 2.53 Max: 10.32
Current: 0.9
During the past 13 years, Cosciens Biopharma's highest PS Ratio was 10.32. The lowest was 0.34. And the median was 2.53.
CSCIF's PS Ratio is ranked better than 93.38% of 936
companies
in the Biotechnology industry
Industry Median: 9.165
vs CSCIF: 0.90
Cosciens Biopharma Inc revenue per share has been in decline for the last 5 years.
During the past 12 months, the average Revenue per Share Growth Rate of Cosciens Biopharma was -25.20% per year.
During the past 3 years, the average Revenue per Share Growth Rate was -32.60% per year.
During the past 5 years, the average Revenue per Share Growth Rate was -18.20% per year.
During the past 10 years, the average Revenue per Share Growth Rate was -4.60% per year.
During the past 13 years, Cosciens Biopharma's highest 3-Year average Revenue per Share Growth Rate was 51.30% per year. The lowest was -36.00% per year. And the median was 7.30% per year.
Back to Basics: PS Ratio
Cosciens Biopharma (OTCPK:CSCIF) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
Cosciens Biopharma PS Ratio Related Terms
Cosciens Biopharma PS Ratio Historical Data
* Premium members only.
The historical data trend for Cosciens Biopharma's PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Cosciens Biopharma's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cosciens Biopharma PS Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Cosciens Biopharma's PS Ratio distribution charts can be found below:
* The bar in red indicates where Cosciens Biopharma's PS Ratio falls into.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
Cosciens Biopharma's Share Price of today is $2.13. Cosciens Biopharma's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $2.40.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Cosciens Biopharma (CSCIF) has a PS Ratio of 0.89 as of Jun. 27, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Cosciens Biopharma and its competitors. This is 65% below median its historical median of 2.53. Over the past decade, Cosciens Biopharma's PS Ratio has ranged from 0.34 to 10.32. According to the industry distribution chart, Cosciens Biopharma ranks #62 out of 936 companies in the Biotechnology industry, placing it in the top 6.6%.
Is Cosciens Biopharma's PS Ratio too high?
Cosciens Biopharma's current PS Ratio of 0.89 is 65% below median its 10-year median of 2.53. Over the past 10 years, this metric has ranged from a low of 0.34 to a high of 10.32. The Biotechnology industry median PS Ratio is 9.17. Cosciens Biopharma's value of 0.89 is 90.3% below this industry median. Based on the distribution chart, Cosciens Biopharma ranks #62 out of 936 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Cosciens Biopharma has a GF Score™ of 60/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Cosciens Biopharma's PS Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Cosciens Biopharma ranks #62 out of 936 companies for PS Ratio. This places Cosciens Biopharma in the top 7% of its industry — outperforming the majority of peers. The industry median PS Ratio is 9.17. Cosciens Biopharma's value of 0.89 is 90.3% below this benchmark. Historically, Cosciens Biopharma's own PS Ratio has ranged from 0.34 to 10.32 over the past decade. While the company's 10-year median is 2.53 vs. the industry median of 9.17, Cosciens Biopharma has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Biotechnology company?
The median PS Ratio among Biotechnology companies is 9.17, based on 936 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Cosciens Biopharma's current PS Ratio of 0.89 is 90.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Cosciens Biopharma and its competitors. For the Biotechnology industry, the median PS Ratio is 9.17 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cosciens Biopharma's current PS Ratio is 0.89, which is 65% below median its own 10-year median of 2.53. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cosciens Biopharma stock overvalued right now?
Based on GuruFocus' analysis, Cosciens Biopharma (CSCIF) is currently considered Modestly Undervalued. The stock's GF Value™ is $2.39, compared to a current price of $2.13 — trading 10.9% below its estimated fair value. The current PS Ratio is 0.89, which is 65% below median its 10-year median of 2.53 and 90.3% below the Biotechnology industry median of 9.17. Cosciens Biopharma's overall GF Score™ is 60/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For Cosciens Biopharma (CSCIF), the current PS Ratio is 0.89 as of Jun. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Cosciens Biopharma (CSCIF) Overvalued in 2026?
Based on GuruFocus' analysis, Cosciens Biopharma stock appears to be undervalued.
The current stock price of $2.13 is trading 10.9% below its estimated GF Value™ of $2.39.
GuruFocus considers Cosciens Biopharma to be Modestly Undervalued.
Key valuation signals for CSCIF:
PS Ratio: 0.89 (65% below median its 10-year median of 2.53)
GF Value™: $2.39 vs. price of $2.13 (10.9% below fair value)
Industry Position: 90.3% below the Biotechnology median (#62 of 936)
No single metric tells the full story. See the CSCIF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Cosciens Biopharma Inc is a biopharmaceutical company developing and commercializing pharmaceutical and diagnostic products and active ingredients for the healthcare and cosmetics industries. It operates through two segments: Active Ingredient and Biopharmaceutical. The Active Ingredient segment, which generates maximum revenue, focuses on plant-based ingredients derived from oats and other renewable resources, including oat beta glucan, oat oil, and avenanthramides. The Biopharmaceutical segment focuses on the development and commercialization of therapeutics and diagnostic tests, including its product Macrilen, and advancing a pre-clinical pipeline targeting unmet medical needs, particularly in rare or orphan indications. It operates in Canada, Germany, the United States, and Austria.
60GF Score
Get the complete analysis for CSCIF
PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CSCIF has been successfully added to your 
